Preclinical and clinical development of palbociclib and future perspectives
Clin. transl. oncol. (Print)
; 20(9): 1136-1144, sept. 2018. ilus, tab
Article
in En
| IBECS
| ID: ibc-173698
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and proliferation in cancer patients. Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and limited toxicity, has been recently approved for the treatment of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor or in combination with fulvestrant in women who have received prior endocrine therapy. This review describes the mechanism of action, preclinical experiences and clinical data of palbociclib, with a special focus on integrating this data with the positioning of palbociclib in the current clinical guidelines for advanced HR-positive/HER2-negative breast cancer. Aspects of the ongoing major studies are also presented, as well as future prospects in the development of palbociclib
RESUMEN
No disponible
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Breast Neoplasms
/
Cyclin-Dependent Kinase Inhibitor p16
/
Cyclin-Dependent Kinase 4
Type of study:
Guideline
Limits:
Animals
/
Humans
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2018
Type:
Article